Guided by a clear strategy and driven by international talent, we are committed to deliver sustainable growth, expand our portfolio, and execute on our strong innovation pipeline to change patients’ lives.
Grünenthal has a strong M&A track record, and we constantly work on the next targeted acquisition to further diversify our portfolio and enhance our profitability. Our focus is on established brands that deliver rapid financial returns, address unmet medical needs, and create synergies across manufacturing, logistics, and commercial operations.
As a leading innovator, we leverage in-house research and business development opportunities to strengthen our pipeline and provide patients with innovative medicines. We apply our expertise in neurobiology, neuronal hyper- and hypoexcitability, sensory biology, neuronal health and neuroinflammation on pain and pain-adjacent indications. Through cutting-edge approaches from systems biology to genetic medicine, we address critical unmet medical needs.
